INmune Bio, Inc.

NASDAQ:INMB

Biotechnology

Healthcare
$1.89 +8.38%

+$0.15 today

Market cap
$50.25M
Beta
0.98
P/E (TTM)
-1.1
EPS (TTM)
-$1.56
52W Low $1.09High $3.24

Volume 0.09M

Average 0.68M

INMB EBITDA Margin

EBITDA as a percentage of revenue.

INmune Bio, Inc.NASDAQ: INMB

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin not reported for Q1 FY2026

Over 3 fiscal years it narrowed by 91337.6 pp.

Context

  • EBITDA Margin widened in 2 of the last 3 fiscal years.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 3 analysts of -14179.6% for the fiscal year ending Dec 2026, up from -91698.0% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
—— QoQ
Last fiscal yearDec 2025
-91698.0%+204937.7 pp YoY
LTMMar 2026
—— YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year+204937.7 pp+77518.4 pp-127419.3 pp
3 years-91337.6 pp+91662.1 pp+182999.7 pp
5 years+91749.0 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-91698.0%
Year-over-year change
+204937.7pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How INMB compares with its peers on the latest reported figures

  • INMB's FY2025 EBITDA Margin of -91698.0% is the lowest of the 2 companies compared; the peer median is -996.8%.
  • Its year-over-year change of +204937.7 pp is the highest of 2, against a peer median of -1077.4 pp.
INMB Competitors Peer median
EBITDA Margin for INMB and competitors
Company Period LTM level YoY 3-year change
XFORX4 Pharmaceuticals, Inc.LTM Mar 2026-996.8% -1077.4 pp—
INMBINmune Bio, Inc.FY2025-91698.0% +204937.7 pp-91337.6 pp
OKUROnKure Therapeutics, Inc.FY2025— ——
PDSBPDS Biotechnology CorporationFY2025— ——
Peer median (excluding INMB) -996.8%-1077.4 pp—

Competitors are the stored peer set for INMB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue181K374K155K14K50K
Cost of Revenue00000
Gross Profit181K374K155K14K50K
Gross Margin100.0%100.0%100.0%100.0%100.0%
Research & Development20.54M17.07M20.27M33.17M20.66M
Selling, General & Admin8.79M9.26M9.62M9.48M10.26M
Operating Expenses29.33M26.33M29.9M42.65M30.92M
Depreciation & Amortization29.15M25.95M29.74M553K84K
EBITDA(1.19M)(1.35M)(267K)(41.53M)(45.85M)
EBITDA Margin-655.8%-360.4%-172.3%-296635.7%-91698.0%
Operating Income(29.15M)(25.95M)(29.74M)(42.64M)(30.87M)
Operating Margin-16106.6%-6938.8%-19187.7%-304535.7%-61738.0%
Interest Income0000850K
Interest Expense00000
Other Income / Expenses(1.19M)(1.35M)(267K)553K(15.06M)
Income Before Tax(30.34M)(27.3M)(30.01M)(42.08M)(45.93M)
Pre-Tax Margin-16762.4%-7299.2%-19360.0%-300585.7%-91866.0%
Income Tax Expense00000
Net Income(30.34M)(27.3M)(30.01M)(42.08M)(45.93M)
Net Margin-16762.4%-7299.2%-19360.0%-300585.7%-91866.0%
EPS (Basic)(1.88)(1.52)(1.67)(2.11)(1.86)
EPS (Diluted)(1.88)(1.52)(1.67)(2.11)(1.86)
Weighted Avg Shares16.13M17.93M17.98M19.94M26.59M
Weighted Avg Shares (Diluted)16.13M17.93M17.98M19.94M26.59M

INmune Bio, Inc.

NASDAQ:INMB

Intrinsic Alpha fair value

Locked

Current Price

$1.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.